Abiraterone acetate clinical trials
14 indexed studies · 4 currently recruiting
- RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
For: Prostate Cancer MetastaticUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
For: Metastatic Prostate Cancer · Prostate AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This study is for men with prostate cancer who are already taking enzalutamide as part of another research study. It aims to gather more information on the long-term safety of enzalutamide when it's helping them. Participants will continue their current treatment and have regular check-ups.
For: Prostate CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
For: Metastatic Castration-resistant Prostate Cancer (mCRPC) · Prostatic NeoplasmsUnited States · Australia · Brazil - Active not recruitingPHASE2, PHASE3
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
This study is looking at a new combination of medicines, abemaciclib, abiraterone acetate, and prednisone, for men with advanced prostate cancer that has spread. It aims to see if adding abemaciclib is safe and effective in treating their cancer.
For: Prostate CancerUnited States · Australia · China - Active not recruitingPHASE3
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is looking at a new combination of medicines for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It aims to see if adding a drug called apalutamide to current treatment helps men live longer without their cancer getting worse.
For: Prostatic NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
This study is looking at a new treatment, Xaluritamig, combined with Abiraterone, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It compares this combination to standard treatments to see if it helps men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
This study looks at a new combination treatment for advanced prostate cancer that has spread. It compares olaparib plus abiraterone with abiraterone alone to see if the new combination works better and is safe for men who haven't had previous strong treatments.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
This study is looking at a new drug, AZD5305, combined with existing hormone therapies for men with prostate cancer that has spread. It aims to see if the combination is safe, how the body handles it, and if it helps treat the cancer.
For: Metastatic Prostate CancerUnited States · Australia · Italy - Active not recruitingPHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
This study is testing a new drug, Saruparib, for men with advanced prostate cancer that is still responding to hormone treatment. It aims to see if adding Saruparib to standard hormone therapy works better than standard therapy alone to slow down cancer growth.
For: Metastatic Castration-Sensitive Prostate CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
This study looks at a new drug, capivasertib, combined with standard treatment (abiraterone and ADT) for men with prostate cancer that has spread and is sensitive to hormone treatment. It's for men whose cancer has a specific change called PTEN deficiency.
For: Hormone-Sensitive Prostate CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
This study is looking at a new prostate cancer drug, JNJ-56021927, alongside existing treatments like abiraterone acetate and prednisone. Researchers want to see if these drugs work well together, check for side effects, and find the best doses for future studies in men with advanced prostate cancer.
For: Prostatic Neoplasms · Metastatic Castration-Resistant Prostate CancerUnited States · Canada · Netherlands - RecruitingPHASE2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
This study looks at a new injection, ASP5541, for advanced prostate cancer that has spread. It compares ASP5541 to a standard tablet treatment, abiraterone acetate, to see how safe and effective it is.
For: Prostate Cancer · Metastatic Castration-Resistant Prostate Cancer · Metastatic Hormone Sensitive Prostate CancerUnited States · China · France - Active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
This study is testing a new combination of medicines, niraparib and abiraterone, with prednisone, for men with advanced prostate cancer that has spread and is resistant to hormone therapy. It compares this new combination against the standard treatment of abiraterone and prednisone to see if it works better.
For: Castration-Resistant Prostatic CancerUnited States · Argentina · Australia